---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117573"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:08:26.109237+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q3 revenue $23.8M, gross profit up 183% YoY; expects adjusted EBITDA profitability in Q4 2023

## Summary
- Net sales $23.8M, highest to-date; concentrates sales $21.6M, up 27% YoY.
- Operating loss $1.7M, improved 53% YoY; net loss $1.9M vs $4.2M in Q3 2022.
- 2023 guidance reaffirmed: net sales $82-86M (+17-18% YoY), gross profit $8-10M (+95-144% YoY).
- Company now expects adjusted EBITDA profitability in Q4 2023, ahead of prior 2024 target.
- Acquired Evoqua hemodialysis concentrates assets; became leading US supplier of liquid bicarbonate.

## SEC filing metadata
- accession: 0001104659-23-117573
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/0001104659-23-117573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/tm2330647d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117573
- JSON: https://secwatch.observer/filing/0001104659-23-117573.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117573.txt

## Key facts
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported the three months ended September 30, 2023 results: revenue $23.8 million. Guidance reaffirmed.
  - Period: the three months ended September 30, 2023
  - Revenue: $23.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: 99.1) --- EX-99.1 2 tm2330647d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rockwell Medical Announces Third Quarter 2023 Results · Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. · Gross profit for the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/0001104659-23-117573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.